These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30156938)

  • 1. Therapeutic Use of Intrathecal Mesenchymal Stem Cells in patients with Multiple Sclerosis: A Pilot Study with Booster Injection.
    Sahraian MA; Mohyeddin Bonab M; Baghbanian SM; Owji M; Naser Moghadasi A
    Immunol Invest; 2019 Feb; 48(2):160-168. PubMed ID: 30156938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
    Harris VK; Vyshkina T; Sadiq SA
    Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
    Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
    Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
    EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
    Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
    Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
    Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study.
    Mohyeddin Bonab M; Yazdanbakhsh S; Lotfi J; Alimoghaddom K; Talebian F; Hooshmand F; Ghavamzadeh A; Nikbin B
    Iran J Immunol; 2007 Mar; 4(1):50-7. PubMed ID: 17652844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.
    Harris VK; Yan QJ; Vyshkina T; Sahabi S; Liu X; Sadiq SA
    J Neurol Sci; 2012 Feb; 313(1-2):167-77. PubMed ID: 21962795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.
    Yamout B; Hourani R; Salti H; Barada W; El-Hajj T; Al-Kutoubi A; Herlopian A; Baz EK; Mahfouz R; Khalil-Hamdan R; Kreidieh NM; El-Sabban M; Bazarbachi A
    J Neuroimmunol; 2010 Oct; 227(1-2):185-9. PubMed ID: 20728948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.
    Dahbour S; Jamali F; Alhattab D; Al-Radaideh A; Ababneh O; Al-Ryalat N; Al-Bdour M; Hourani B; Msallam M; Rasheed M; Huneiti A; Bahou Y; Tarawneh E; Awidi A
    CNS Neurosci Ther; 2017 Nov; 23(11):866-874. PubMed ID: 28961381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
    Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
    Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious Adverse Events Have Not Been Reported with Spinal Intrathecal Injection of Mesenchymal Stem Cells: A Systematic Review.
    Barmada A; Sharan J; Band N; Prodromos C
    Curr Stem Cell Res Ther; 2023; 18(6):829-833. PubMed ID: 35980065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells as a treatment for multiple sclerosis: a focus on experimental animal studies.
    Lotfy A; Ali NS; Abdelgawad M; Salama M
    Rev Neurosci; 2020 Jan; 31(2):161-179. PubMed ID: 31605598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.
    Bonab MM; Sahraian MA; Aghsaie A; Karvigh SA; Hosseinian SM; Nikbin B; Lotfi J; Khorramnia S; Motamed MR; Togha M; Harirchian MH; Moghadam NB; Alikhani K; Yadegari S; Jafarian S; Gheini MR
    Curr Stem Cell Res Ther; 2012 Nov; 7(6):407-14. PubMed ID: 23061813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis.
    Vaheb S; Afshin S; Ghoshouni H; Ghaffary EM; Farzan M; Shaygannejad V; Thapa S; Zabeti A; Mirmosayyeb O
    Mult Scler Relat Disord; 2024 Jul; 87():105681. PubMed ID: 38838423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrathecal Injection of Allogenic Bone Marrow-Derived Mesenchymal Stromal Cells in Treatment of Patients with Severe Ischemic Stroke: Study Protocol for a Randomized Controlled Observer-Blinded Trial.
    Deng L; Peng Q; Wang H; Pan J; Zhou Y; Pan K; Li J; Wu Y; Wang Y
    Transl Stroke Res; 2019 Apr; 10(2):170-177. PubMed ID: 29796934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis.
    Petrou P; Kassis I; Ginzberg A; Hallimi M; Karussis D
    Stem Cells Transl Med; 2022 Mar; 11(1):55-58. PubMed ID: 35641166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple transplantation of mesenchymal stem cells in a patient with active progressive multiple sclerosis: Long term therapeutic outcomes.
    Liu S; Mao X; Hou Z; Wei H; Gao H; Liu Y; Xie Y; Tang W; He S; Zhao Y; Wang W; Li L; Wang X; Meng M
    Clin Neurol Neurosurg; 2022 Dec; 223():107475. PubMed ID: 36274549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study.
    Satti HS; Waheed A; Ahmed P; Ahmed K; Akram Z; Aziz T; Satti TM; Shahbaz N; Khan MA; Malik SA
    Cytotherapy; 2016 Apr; 18(4):518-22. PubMed ID: 26971680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.